Literature DB >> 8816395

Requirements for induction of vitamin D-mediated gene regulation in normal human B lymphocytes.

J W Morgan1, D M Morgan, S R Lasky, D Ford, N Kouttab, A L Maizel.   

Abstract

Mature human lymphocytes are unique targets of 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)2D3) in that vitamin D receptors (VDR) are not constitutively expressed, and specific cellular activation signals are required for both the up-regulation of VDR and establishment of reactivity to the lipophilic ligand. Treatment of B lymphocytes with the cytokine IL-4 (IL-4), in the absence of prior activation, induces a weak up-regulation of VDR expression but fails to generate vitamin D-responsive element (VDRE)-reactive nuclear protein complexes or to initiate the genomic transcription of 25-hydroxyvitamin D3 24-hydroxylase. Stimulation of B lymphocytes by either ligation of CD40 Ag or cross-linking the Ig receptor is also insufficient to render B lymphocytes responsive to 1 alpha,25(OH)2D3. However, this apparent lack of response to the secosterol can be overcome by stimulation of B lymphocytes with a combination of these cellular activation signals, which are sufficient to lead to G1 cell cycle progression. In the presence of 1 alpha,25(OH)2D3, cellular activation associated with stimulation of such a progression appears to be sufficient for the up-regulation of VDR message and protein and necessary for the establishment of VDRE binding complexes and the induction of 24-hydroxylase message. Furthermore, biologic functions are modulated, in that the hormone inhibits proliferation in a subset of the activated B cells. These observations suggest that reactivity to 1 alpha,25(OH)2D3 is tightly regulated in B lymphocytes, requiring specific signals for its initiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816395

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Authors:  Paige M Kulling; Kristine C Olson; Thomas L Olson; Cait E Hamele; Kathryn N Carter; David J Feith; Thomas P Loughran
Journal:  J Steroid Biochem Mol Biol       Date:  2017-07-20       Impact factor: 4.292

Review 2.  Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?

Authors:  Varsha Singh
Journal:  Curr Nutr Rep       Date:  2020-09

3.  Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults.

Authors:  Allison Bearden; Cybele Abad; Ron Gangnon; James M Sosman; Neil Binkley; Nasia Safdar
Journal:  J Clin Endocrinol Metab       Date:  2013-03-01       Impact factor: 5.958

4.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

5.  1alpha,25-dihydroxyvitamin D3 increases IgA serum antibody responses and IgA antibody-secreting cell numbers in the Peyer's patches of pigs after intramuscular immunization.

Authors:  Y Van Der Stede; T Verfaillie; E Cox; F Verdonck; B M Goddeeris
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

6.  Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma.

Authors:  Christoph Renné; Alexander H Benz; Martin L Hansmann
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

7.  Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D.

Authors:  Duncan M Gascoyne; Linden Lyne; Hayley Spearman; Francesca M Buffa; Elizabeth J Soilleux; Alison H Banham
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

8.  1,25 (OH)2D3 treatment alters the granulomatous response in M. tuberculosis infected mice.

Authors:  Kamlesh Bhatt; Wasiulla Rafi; Neel Shah; Sylvia Christakos; Padmini Salgame
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.